C6 LYME ELISA

C6 LYME (B.burgdorferi, ELISA) is comparable in specificity to the immunoblot/Western blot assay, but is more sensitive than the 

confirmatory tests.

High specificity and sensitivity values are associated with the use of recombinant protein antigen (peptide C6) in this assay in a microplate ELISA format. Peptide C6 (IR6) is the 26-amino acid sequence of the intramembrane protein VlsE. VlsE is a major highly specific and sensitive marker in the laboratory diagnosis of Lyme disease. The VlsE protein (surface expressed lipoprotein with Extensive antigenic variation) is expressed in vivo and shortly after infection.

One region of VlsE is conserved and highly immunogenic in the infected person, inducing the production of IgG and IgM. The C6 peptide sequence is highly antigenically reactive, generating an immune response in almost all human cases shortly after infection and is specific for Borrelia strains causing Lyme disease.

The C6 peptide is not found in other pathogens and the use of its recombinant version minimizes the possibility of cross-reactions.

Benefits of C6 LYME:

• Specificity of Western blot in ELISA format
• Sensitive for detection of antibodies in early stage and acute Lyme disease
• Due to high specificity, it reduces the number of false positives at the screening stage
• Detects antibodies to all Borrelia species that cause Lyme disease, including the European strains B. garinii and B.afzelii.
• Cost-effective. Significantly reduces the cost of performing confirmatory tests in screening examinations

C6 LYME ELISA is performed by the laboratory ArminLabs GmbH